The aim of this systematic literature review is to investigate which types of patient participation in medication reviews have been practiced and what is known about the effects of patient participation within the medication review process.
Introduction
Patient participation is seen as the key to modern health care and has been widely implemented in medical decision-making and the management of chronic diseases. 1 The World Health Organization (WHO) programme Patients for Patient Safety also emphasizes the central role patients should play in efforts to improve the quality and safety of health care. 2 Positive effects of a structured two-way communication between patients and healthcare professionals can be increased patient knowledge, adherence, and satisfaction. 3 With respect to pharmaceutical care, patient participation is thought to improve concordance between the patient and the healthcare provider on the pharmacotherapy. 3 It is also suggested that involvement of patients in pharmaceutical interventions, such as medication reviews, is important for motivation to change and long-term effectiveness of pharmacotherapy. 4 The UK National Prescribing Centre defines a medication review as 'a structured, critical examination of a patient's medicines with the objective of reaching an agreement with the patient about treatment, optimising the impact of medicines, and minimising the number of drug related problems'. 5 Drug related problems (DRPs) frequently occur in elderly and can be drug interactions, inefficacy of treatment, adverse drug reactions, prescription errors but also noncompliance with treatment and user problems. The medication review definition includes patient participation in the medication review process and agreement between patient, physician and about the treatment.
The definition of patient participation is not self-evident. Patient participation, patient collaboration, patient involvement, partnership, patient empowerment or patient-centered care, are used interchangeably. 1 Street and Millay defined patient participation in medical consultations as "the extent to which patients influence the content and the structure of the interaction as well as the health care provider's beliefs and behaviour by, for example, asking questions, descriptions of health experiences, expressing concerns, giving opinions, making suggestions and stating preferences". 6 
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Chapter 2 Thompson et al. 2007 defined levels of patient involvement from the patient perspective. 7 Parallel to a literature-based ranking of professional-determined levels of involvement, Thompson, on the basis of a comprehensive qualitative data, defined several levels of patient-desired involvement (table 2.1). This follows the three decision making models, paternalistic, informed and professional-as-agent of Charles et al. 8 Participation is seen as being codetermined by patients and professionals and occurring only through the reciprocal relationships of dialogue and shared decision making. In a dialogue the patient gives information and there is consultation by the professional, in shared decision making the professional acts as agent. The model and definition of Thompson is used in this research. 7 Furthermore, giving information during a dialogue between patient and caregiver has a different purpose than shared or informed decision making. In the context of medication reviews, patient input is needed as preparation for the medication review, to incorporate the patient's perspective. The purpose of information giving by the caregiver is mainly educational. On the other hand there is the decision making process, where the purpose is to make a joint decision.
Active patient participation in medication reviews is increasingly recognized as a prerequisite for a successful medication review and consequently in optimal pharmacotherapy and acknowledged in international and recent Dutch guidelines. 5, [9] [10] [11] In the field of treatment counselling, especially for oncology and e.g., there is indeed evidence that the involvement of patients and shared-decision making led to more satisfied patients, better adherence to therapy and better health outcomes. [12] [13] [14] However, little is known about the effects of patient participation in medication reviews on patient outcomes. Before studying possible effects of patient participation, the different types of patient participation researched must be identified. The aim of this systematic literature review is to investigate which types of patient participation in medication reviews have been practiced and what is known about the effects of patient participation within the medication review process. The following research questions were formulated:
1. Which types of patient participation in medication reviews have been researched? 33 2. What are the effects of patient participation in medication reviews on drug related problems (DRPs) and other patient outcomes? 
Methods
A systematic literature review was conducted following the PRISMA statement. 15 A literature search was performed in the databases PubMed, EMBASE, CINAHL, and Cochrane Library in July 2013. A search strategy was developed by the first author (FW) and an experienced information specialist (Supplementary Material I). The search strategy combined different synonyms and related terms of patient participation with synonyms of medication reviews. Inclusion-and exclusion criteria for articles are displayed in box 2.1. In addition, the references from all included articles were also examined for relevant articles. Three types of medication reviews can be distinguished based on the data used: 1) clinical medication reviews are based on medication records, medical records and patient data, 2) concordance and compliance medication reviews are based on medication records and patient data, and 3) prescription reviews are based on medication records only, so without patient data. 16 In the present literature review only clinical medication reviews or concordance and compliance reviews 6 , have been included. According to Thompson' • Child or adolescent population;
• Studies in the palliative care setting.
• Articles in other languages than English or Dutch
Selection procedure
The selection procedure of relevant articles included three steps, 1. Screening of title and abstract, 2. Full-text based selection, and 3. Quality assessment (figure 2.1). References of selected articles were also screened for relevant articles and extra articles could be added on the basis of expert opinion. Two authors (FW, PJME) screened all 1,257 titles and abstracts independently. In case of doubt, an article was included for full-text review. The first 50 titles and abstracts were screened and discussed to reach agreement on interpretations, definitions and in-and exclusion criteria. After screening all titles and abstracts, consensus was reached in a consensus meeting for all disagreements. In total, 133 articles were selected for full-text review. The measure of agreement between the reviewers, Cohen's Kappa (ĸ) was calculated.
The first author screened all 133 full-text articles on in-and exclusion criteria according to box 2.1. In case of any doubt, the full-text article was 35 discussed with at least one other author. In total, 37 articles were selected for quality assessment and included in this literature review, of which one was obtained from the references of the selected articles, and one article was added on the basis of expert opinion.
Quality assessment
Quality assessment was carried out independently by three authors (FW, PJME, JGH) for all 37 articles. One reviewer (FW) assessed all relevant full-text articles and two other reviewers (PJME, JGH) assessed both half of the articles, independently of each other.
The complexity and heterogeneity of the articles for the first research question required a specific qualitative assessment based on the description of information about patient participation and whether an evaluation was carried out. Mainly, the completeness of reporting was assessed, assuming a correlation with the quality of reporting and the quality of the study. For the second research question, again articles were very heterogenic, and studies were mainly of an observational or qualitative nature. Existing tools were used, with minimally adaptions, to assess the quality of the article. Three checklists are used, dependent on the literature review objective and whether the results were quantitative or qualitative (box 2.2).
Strong, moderate or weak final ratings were given based on predefined criteria. Quality assessment tools were piloted with ten articles by the reviewers and differences in assessment were discussed. Disagreements in final ratings were discussed with a fourth reviewer (FGS). Qualitative assessment on adequacy of the description of patient participation and evaluation of patient participation. The following questions were included in the checklist, which consisted of two sub ratings; description and evaluation of patient participation. 17 This tool has been judged suitable to be used in systematic literature reviews of effectiveness, had fair inter-rater agreement in individual domain scoring and excellent agreement in final grade assigned to among raters and has been reported to have content and construct validity. 18 The questions on blinding were not applicable for this topic. Nine articles were assessed with this checklist.
Description of patient participation
3. Checklist for qualitative studies: Methodological quality of studies on the evaluation of patient participation. This checklist is based on the detailed questions of the CASP qualitative checklist. The CASP checklists have been evaluated, pilot tested in workshops, including feedback and review of materials, using successively broader audiences. Weak, moderate and strong ratings were assigned based on the number of 'yes answers'. 19 Seven qualitative articles were assessed with this checklist. 2. Type of information given by the patient for the medication review; 3. Kind of consultation by the professional to the patient on the medication; 4. Evaluation of the patient participation. Qualitative studies are described separately in overview tables with the description and evaluation of the patient participation. When present, data on the effects of patient participation was collected, specifically on DRPs and possible other outcomes. All data were analysed in a descriptive manner for the results section and summarized in overview tables.
Data extraction and analyses

Results
General characteristics of publications
The authors who reviewed all titles and abstracts, reached strong agreement (Cohen's ĸ=0.73). General characteristics of all 37 included publications are presented in table 2.2.
20-56 All studies described medication reviews, but none of the studies was an RCT on the effectiveness of patient participation. In total, 30 studies were of a quantitative nature with different study designs, six publications had qualitative designs. Half of the studies were carried out in Europe, mainly the UK, The Netherlands and Norway, the other half was mainly from the USA and Australia. Almost all studies were carried out in elderly with a variety of risk factors for medication problems, such as polypharmacy, multimorbidity, recent hospital admission or specific diseases. More than a third of the quantitative studies were small scale or pilot studies with less than 100 participants. The majority of the medication reviews was carried out by pharmacists or pharmacists in cooperation with general practitioners (GPs).
Of the 30 articles assessed with the checklist for quantitative studies on description and evaluation of patient participations, 20 articles had a final 39 moderate rating, five a strong rating and five a weak rating. All but one of the qualitative studies were assessed with a strong rating. Of the nine articles that were assessed with the quality assessment for effects of patient participation, five articles had a moderate and four a weak rating. Overall, the description of the involvement of patients in the medication review process in all publications was minimal. Only studies in which the patient gave information to the professional (level 2 in table 2.1) were found. Of the 37 publications, 14 studies included home visits, 14 included patient interviews at the pharmacy or in the GP office, four studies involved patients during or at discharge of their hospital stay and five studies used mixed or other methods to involve the patient. Communication with the patient, especially as preparation before the medication review, was most often carried out by the pharmacist or jointly by the pharmacist and GP. Furthermore, one third of the studies mentioned the duration of the patient contact with the healthcare professional; the time investment ranged between 15-90 minutes per patient.
Information exchange between patient and healthcare professional
In all studies patients provided information about their actual drug use. Additional information included knowledge about the medicines they used, adverse drug events, allergies, adherence and compliance, perceived effectiveness, practical or management problems, lifestyle and social support related, hoarding problems and attitude towards certain medicines. Healthcare professionals counseled patients often about proposed changes in medication, education on their medication, lifestyle or health problems and gave follow-up instructions for medication monitoring, laboratory tests or new visits.
Evaluation of patient participation
In some studies the involvement of patients during medication reviews was evaluated. Information on actual drug use often added new information to the records e.g. on prescribed drugs, over the counter (OTC) drugs, compliance, adherence or other drug user problems. 23, 24, 27, 30, 37, 48 Several studies carried out a satisfaction survey among patients who participated in medication review programs. The majority of the patients was satisfied with the review services and indicated to have increased knowledge and was able to ask questions about their medications. Two British qualitative studies 38, 48 observed that patients were not actively involved in the consultations with pharmacists for their medication review and did ask very few questions. Furthermore, in three qualitative studies 40, 42, 51 , patients called on the higher authority of the GP or specialist above the pharmacists to discuss their medicines (table 2.4).
Effects of patient participation
The effects of patient participation in medication reviews on DRPs or other patient outcomes have been described in nine studies (table 2.5). 20, 26, 27, [29] [30] [31] 39, 49, 50 Of all DRPs identified, 27% to 73% were found as result of a patient interview. Many of these problems would not have been identified if only medication or medical records were used. In two Dutch studies 27, 30 , the DRPs identified in the interviews were also assigned a higher priority or the recommendations based on patient information were more often implemented than problems identified through medication records or in the medical history. Some other studies mentioned the type of DRPs, which was interpreted as originating from the patient interview. 21, 23, 24, 37 However, these results are not included in this literature review to answer the effects research questions, because it is not described how and if patient's involvement led to these effects. The studies that showed effects on DRPs were assessed with higher quality on description and evaluation of patient participation than studies that reported no effect data. One study found no difference in quality of life after the medication review between patients who were enabled to participated and control patients. However, in this study very few patients actively participated in the medication review process and the sample size was too small to assess quality of life differences. 39 There was no difference in effects or level of patient involvement between different care settings, e.g. hospital or community, or for specific patient groups versus less specific, general polypharmacy or multi-morbidity patients. Interview in pharmacy by pharmacist -Actual drug use Not described -Expression of satisfaction and gratitude -Better understanding of medicines -Re-assurement (for patients) that they were taking medicines correctly -Learning things about medications that they not knew before
Strong
OTC=Over The Counter medicines; MUR=Medication Use Review 
Discussion
The type of patient participation commonly practiced in the studies reviewed was information giving and was often the starting point in a medication review.
Other types of patient participation were not found. The information given by the patient was mainly on actual drug use and adherence problems. In most studies the professional was a pharmacist who interviewed or counseled patients at home, in the pharmacy or in the hospital. The involvement of patients led to identification of more drug related problems. These DRPs were considered more relevant, had a higher priority and treatment recommendations based on these problems had a better implementation rate. Both patients and professionals indicated to be satisfied with the patient participation. Some studies suggested increased medication knowledge and patients' understanding. The effects of patient participation is hardly studied and poorly described in current literature. We found no evidence the patient involvement in medication reviews went further than information exchange during dialogues or interviews between patients and caregiver. It remains unclear how patients participate in subsequent stages of the medication review with regard to the sharing of information, decision-making, counseling and implementation of possible medication changes.
The exact contribution of patient participation to the effects of the study was mostly unclear. Studies with higher quality often reported effects of patient participation on the identification of DRPs. Weaker quality studies reported good patients' satisfaction, increased medication knowledge and patients' understanding. These outcomes, however, were measured in surveys with low response rates, which could have led to response bias.
In national and international guidelines, patient participation in a medication review process is a prerequisite for a successful medication review. 5, 10, 11 However, guideline recommendations to involve patients are not based on evidence but on prevailing societal considerations expert opinions.
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Apparently, there is a discrepancy between patient-centeredness and evidence-based care. Patient participation is a concept that already arises from the sixties, when the consumer protection rights were introduced in the US Congress; "the right to safety, the right to be informed, the right to choose and the right to be heard". 57 This also implicates that patient participation is more a right and largely justified on humane reasons than an evidence-based means to improve treatment outcomes, as is questioned before. 58, 59 The use of medication reviews, particularly with active patient involvement, as an intervention to improve treatment results is a fairly recent development in pharmaceutical care. This may partly explain the absence of good quality literature clearly describing involvement of patients in medication reviews and its effects. Furthermore, implementing patient participation is strongly dependent on overcoming healthcare professionals' obstacles such as time constraints and finances, societal norms and the tendency of caregiver to maintain control. 1 Particularly, the time investment to involve patients in the medications reviews process is considerable, and hence costly. In this literature review, it varied between 15-90 minutes for patients interviews aimed only to inform caregivers on actual drug use and experiences. As compared to younger patient, elderly are known to participate less in care and self-management and have different preferences for involvement and decision making. 60 This literature review consisted of studies almost solely in elderly subjects, which is the main target group for medication reviews. This means that the patient group described in this literature study is already less prone to participate and to a lesser extent wants to be involved in medical decisions. Not all patients want to or can be involved and the extent to which involvement is useful may depend on age, disease severity, acuteness of the disease, cognitive state, comorbidity, health literacy, socio-economic status, type and impact of decision, attitudes towards medication and prevention, patient-professional relationships and other personal preferences. 1, 7 Previous research also indicated that patients have a desire to participate in the consultation, but do not always feel a need to be involved in medical decision and patient involvement was limited to information sharing. 59, [61] [62] [63] This means that we may have to reconsider how and which patients should be involved in a medication review. Data on the gain of patient participation in terms of effects is scarce and existing literature has a weak quality. The evidence for the effects on clinical patient outcomes such as quality of life, hospitalisation and mortality of medication reviews themselves is limited. 64 Although, patient participation in consultations has been suggested to improve e.g., adherence, long-term effects of pharmacotherapy and thereby indirect patient outcomes. 3, 4 However no evidence was found for this in the context of medication reviews. There are some limitations to discuss. The taxonomy by Thompson 7 used in this study is not very discriminative. There may be other in-between combinations applicable, however others also recognize that labelling these would not be very useful since one always deals with specific situational contexts. 65 This emphasizes the complexity of studying patient participation.
Although an extensive search strategy in four literature databases was used and an additional hand search in reference lists was performed, relevant articles may have been missed.
The complexity of patient participation in medication reviews makes it difficult to design comparative studies. Moreover, it is difficult to measure to specific contribution of patient participation on treatment outcomes. To study whether e.g. shared-decision making is carried out in practice, a qualitative study design may be needed. With qualitative observational research one could study whether patients really influence the content and structure of the interaction of a consultation or decision, like Street and Millays' definition of patient participation. 6 To study whether patient participations also results in effects, future research should focus on designs, possibly comparative, with a mixed character with relevant, quantitative patient outcomes such as adherence, quality of life, adverse drug events and patient satisfaction and qualitatively on the level of involvement of patients by observing consultations.
Conclusion
To conclude, patient participation in medication reviews is important to gain information about patient preferences and relevant drug related problems. Patient participation is not common and not always desirable in decision making in the last phase of a medication review. As there is often no clear decision as with treatment counselling and the target group for medication reviews, vulnerable elderly, does not always have the wish to be involved in the actual decision. Patient satisfaction and knowledge seem to improve when 59 patients are more involved, however no effects in health outcomes have been observed.
Patient participation in medication reviews is desirable and may improve patient outcomes, but is presently based on expert opinions and ethical considerations for modern healthcare, rather than on evidence. Considering the time investment and limited evidence of patient participation in medication reviews efficient methods targeted at the right patients seem appropriate. The profit of higher levels of patient communication and shared decision making is until now, not supported by evidence of its effectiveness. Since patient involvement limited to information sharing seems more appropriate, efficient methods to involve patients in medication reviews are topic for future research and practice innovations. In this way, clinical medication reviews will become more feasible for GPs and pharmacists.
Practice implications
Our results may have potential implications for pharmacists, GPs or other physicians who perform medication reviews. Patient participation at the level of information giving, may improve information of the professionals and identification of DRPs and may contribute to improved patient knowledge, understanding and patients' satisfaction. Physicians and pharmacists have to keep in mind that involvement of patients during decision making is not primarily evidence-based to improve the outcomes of both medication review outcomes as well as and patient outcomes and is not always needed in this type of decisions. Based on the literature, information giving participation during medication reviews improves the medication review process and identification of drug related problems, however evidence regarding the effectiveness of higher levels are lacking and might not be needed at all times and at all costs.
